Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia - A Clinical Research Center study

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 3, 1996, Pages 1031-1034

  Tollin, Steven R ^a,b   Rosen, Harold N ^a   Zurowski, Kristine ^a   Saltzman, Brian ^a   Zeind, A John ^a   Berg, Solomon ^a   Greenspan, Susan L ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FINASTERIDE; OSTEOCALCIN;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; DUAL ENERGY X RAY ABSORPTIOMETRY; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT;

AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; DIHYDROTESTOSTERONE; FINASTERIDE; HUMANS; MALE; PARATHYROID HORMONE; PROSTATIC HYPERPLASIA;

EID: 0029961690     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.3.1031     Document Type: Article

References (20)

1. Gormley GJ, Stoner E, Rittmaster RS, et al. 1990 Effects of finasteride (MK-906), a 5-alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 70:1136-1141.
2. Resnick NM, Greenspan SL. 1989 'Senile' osteoporosis reconsidered. JAMA. 261:1025-1029.
3. Jackson JA, Kleerekoper M. 1990 Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine. 69:137-151.
4. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley Jr WF. 1987 Osteoporosis in men with idiopathic hvpogonadotropic hypogonadism. Ann Intern Med. 106:354-361.
5. Greenspan SL, Neer RM, Ridgway EC, Klibanski A. 1986 Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 104:777-782.
6. Verhas M, Schoutens A, L'Hermite-Baleriaux M, et al. 1986 The effect of orchidectomy on bone metabolism in aging rats. Calcif Tissue Int. 39:74-77.
7. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. 1989 Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab. 69:523-527.
8. Schweikert HU, Rulf W, Niederle N, Schafer HE, Keck E, Kruck F. 1980 Testosterone metabolism in human bone. Acta Endocrinol (Copenh). 95:258-264.
9. Paffenbarger Jr RS, Wing AL, Hyde RT. 1978 Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol. 108:161-175.
10. Krall EA, Sahyoun N, Tannenbaum S, Dallal GE, Dawson-Hughes B. 1989 Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N Engl J Med. 321:1777-1783.
11. van den Brink HR, Lems WF, van Everdingen AA, Bijlsma JWJ. 1993 Adjuvant oestrogen treatment increases bone mineral density in postmenopausal women with rheumatoid arthritis. Ann Rheum Dis. 52:302-305.
12. Rosen HN, Dresner-Pollak R, Moses AC, et al. 1994 Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int. 54:26-29.
13. Koevoet AL, Baars JB. 1969 The determination of urinary hydroxyproline. Clin Chim Acta. 25:39-43.
14. Matsuki H, Kasuga H, Sugita M, Osaka F, Yokoyama H. 1984 An improved method for analysis of urinary hydroxyproline by an automated analyzer. Tokai J Exp Clin Med. 9:421-428.
15. Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 7:1251-1258.
16. Gertz BJ, Shao P, Hanson DA, et al. 1994 Monitoring bone resorption in early postmenopausal women by an immunoassay tor cross-linked collagen peptides in urine. J Bone Miner Res. 9:135-142
17. Rittmaster RS. 1994 Finasteride. N Engl J Med. 330:120-125.
18. Gormley GJ, Stoner E, Bruskewitz RC, et al. 1992 The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1185-1191.
19. Matzkin H, Chen J, Weisman Y, et al. 1992 Prolonged treatment with finasteride (a 5-alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf). 37:432-436.
20. Rosen HN, Tollin S, Balena R, et al. 1995 Bone density is normal in male rats treated with finasteride. Endocrinology. 136:1381-1387.